You just read:

NOVAVAX and University of Massachusetts Medical School Publish Preclinical Safety and Efficacy Study of a Respiratory Syncytial Virus (RSV) Virus-like Particle (VLP) Vaccine Candidate

News provided by

Novavax, Inc.

Dec 22, 2010, 08:00 EST